lapatinib - Ontology Report - Rat Genome Database

lapatinib results in decreased activity of ABCB11 protein

PMID:20829430 PMID:23956101 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

Abcb1a

ATP binding cassette subfamily B member 1A

multiple interactions

lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]

PMID:18829547

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

Abcb4

ATP binding cassette subfamily B member 4

decreases activity

lapatinib results in decreased activity of ABCB4 protein

PMID:28437613

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

Abcg2

ATP binding cassette subfamily G member 2

multiple interactions

lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]

PMID:18829547

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

Acta2

actin alpha 2, smooth muscle

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

Akt1

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation
decreases activity
decreases expression

[Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
Lapatinib results in decreased phosphorylation of AKT1 protein
lapatinib results in decreased activity of AKT1 protein
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form

PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More...

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

Aldh1a1

aldehyde dehydrogenase 1 family, member A1

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

Bax

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]

PMID:29387217 PMID:32890875

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

Bcl2

BCL2, apoptosis regulator

decreases expression
multiple interactions

Lapatinib results in decreased expression of BCL2 protein
2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]

PMID:29387217 PMID:32890875

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

Birc5

baculoviral IAP repeat-containing 5

decreases expression

lapatinib results in decreased expression of BIRC5 protein

PMID:16091755

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

Bnip3

BCL2 interacting protein 3

multiple interactions

Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA]

PMID:25981168

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

Casp3

caspase 3

increases cleavage
multiple interactions

Lapatinib results in increased cleavage of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]

PMID:29387217 PMID:32890875

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

Casp9

caspase 9

multiple interactions
increases cleavage

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]

PMID:29387217

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

Ccna2

cyclin A2

decreases expression

lapatinib results in decreased expression of CCNA2 protein

PMID:25221644

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

Ccnd1

cyclin D1

multiple interactions
decreases expression

2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein

PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

Ccne1

cyclin E1

multiple interactions

[afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]

PMID:15665275

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

Cd24

CD24 molecule

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein

NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662

Cd44

CD44 molecule (Indian blood group)

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]]

PMID:26643609 PMID:33396024

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

Cdh1

cadherin 1

multiple interactions

[Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein]

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

Cdh2

cadherin 2

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

Cdk2

cyclin dependent kinase 2

multiple interactions

PMID:15665275

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

Cdkn1a

cyclin-dependent kinase inhibitor 1A

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

Cdkn1b

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression

[afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein

PMID:15665275 PMID:20701607 PMID:32890875

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

Cyp1a1

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Lapatinib results in decreased activity of CYP1A1 protein

PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

Cyp1b1

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Lapatinib results in decreased activity of CYP1B1 protein

PMID:33814510

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

Cyp3a2

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing
multiple interactions

CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA

PMID:26958860 PMID:33259822

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

Cyp3a9

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing
multiple interactions

CYP3A5 protein results in increased metabolism of lapatinib
[CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

Egfr

epidermal growth factor receptor

decreases activity
affects response to substance
multiple interactions

lapatinib results in decreased activity of EGFR protein
EGFR protein affects the susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

Erbb2

erb-b2 receptor tyrosine kinase 2

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased phosphorylation of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased activity of ERBB2 protein

PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More...

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

Erbb3

erb-b2 receptor tyrosine kinase 3

decreases expression
decreases activity

lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein

PMID:19435893 PMID:19509167

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

Esr1

estrogen receptor 1

decreases activity
multiple interactions

lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein

PMID:15665275

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

Gpt

glutamic--pyruvic transaminase

increases secretion

Lapatinib results in increased secretion of GPT protein

PMID:29655783

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

Hif1a

hypoxia inducible factor 1 subunit alpha

multiple interactions

PMID:25981168 PMID:32890875

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

Hmox1

heme oxygenase 1

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

Jak2

Janus kinase 2

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein]

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

Kras

KRAS proto-oncogene, GTPase

decreases response to substance
multiple interactions

KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]

PMID:28739874

NCBI chr 4:178,185,418...178,218,484

Mapk1

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased phosphorylation of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased activity of MAPK1 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

Mapk12

mitogen-activated protein kinase 12

multiple interactions

lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]

PMID:28739874

NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664

Mapk3

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation
decreases expression
decreases activity

ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased phosphorylation of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased activity of MAPK3 protein

PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More...

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

Mcm7

minichromosome maintenance complex component 7

multiple interactions
decreases expression

ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein]

PMID:25221644

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

Mtor

mechanistic target of rapamycin kinase

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

Nfe2l2

NFE2 like bZIP transcription factor 2

multiple interactions
increases activity

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

Nqo1

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

Parp1

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; 2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]

PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

Pcna

proliferating cell nuclear antigen

multiple interactions

2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]

PMID:32890875 PMID:33396024

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

Ptgs2

prostaglandin-endoperoxide synthase 2

multiple interactions

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

Ptpn3

protein tyrosine phosphatase, non-receptor type 3

multiple interactions

lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]

PMID:28739874

NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443

Raf1

Raf-1 proto-oncogene, serine/threonine kinase

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

Rb1

RB transcriptional corepressor 1

multiple interactions

Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein]

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

Rela

RELA proto-oncogene, NF-kB subunit

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

Snai1

snail family transcriptional repressor 1

multiple interactions
decreases response to substance

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib

PMID:26643609 PMID:32890875 PMID:33396024

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

Snai2

snail family transcriptional repressor 2

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]]

PMID:33396024

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

Sod1

superoxide dismutase 1

multiple interactions

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

Sod2

superoxide dismutase 2

multiple interactions
increases expression

[CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

Sox2

SRY-box transcription factor 2

multiple interactions

[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

Src

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein]

PMID:26643609 PMID:32890875

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

Stat3

signal transducer and activator of transcription 3

multiple interactions

Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein]

PMID:32890875 PMID:33396024

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

Tgfb1

transforming growth factor, beta 1

decreases response to substance

TGFB1 protein results in decreased susceptibility to lapatinib

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

Twist1

twist family bHLH transcription factor 1

multiple interactions

Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]]

PMID:33396024

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

Ugt1a2

UDP glucuronosyltransferase 1 family, polypeptide A2

decreases activity
multiple interactions

Lapatinib results in decreased activity of UGT1A3 protein
[Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of obeticholic acid; [Lapatinib results in decreased activity of UGT1A3 protein] which results in decreased glucuronidation of Ursodeoxycholic Acid

PMID:31299240

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

Vegfa

vascular endothelial growth factor A

multiple interactions

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

Vim

vimentin

multiple interactions

[Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VIM protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of VIM protein]